Chitosan and Salvia injection in interventional fallopian tube recanalization

Abstract

Objective To investigate the clinical value of using the injection of Chitosan, Salvia injection, and Chitosan and Salvia in interventional fallopian tube recanalization (FTR) , and to determine the mechanism of Chitosan and Salvia injection in the prevention of postoperative recurrence of tubal adhesion and the promotion of tissue repair, for more effective method to prevent tubal adhesion and improve intrauterine pregnancy rate. Methods A total of 400 patients with tubal obstruction were randomly divided into the control group (n=100) , Chitosan group (n=100) , Salvia group (n=100) , and Chitosan and Salvia injection group (n=100). The control group was injected with liquid-releasing agent for anti-inflammatory treatment. The Chitosan group was injected with liquid-releasing agent for anti-inflammatory treatment, and then was injected with Chitosan to prevent tubal adhesion. The Salvia group was injected with liquid-releasing agent, and then was injected with Salvia. The Chitosan and Salvia injection group was injected with liquid-releasing agent, and then was injected with Chitosan and Salvia injection. The location of tubal obstruction and interventional FTR rate were determined during operation. The patency rate of hydrotubation in each group was followed up at 3 months after the operation. The pregnancy rate in each group was followed up at 12 months after the operation. Results There were 400 patients with a total of 800 fallopian tubes, including 316 tubal obstructions at isthmus portion and 364 tubal obstructions at interstitial portion. (1) Interventional FTR rate: The interventional FTR rate in the control group, Chitosan group, Salvia group, and Chitosan and Salvia injection group was 94.1% (159/169) , 97.1% (170/175) , 96.5% (166/172) and 98.2% (173/176) , respectively. There were no statistically significant differences among the groups (P>0.05). (2) The patency rate of hydrotubation at 3 months after the operation: The patency rate of hydrotubation at 3 months after the operation in the Chitosan and Salvia injection group (90.9%, 160/176) , Chitosan group (88%, 154/175) and Salvia group (85.2%, 145/170) was significantly higher than that in the control group (73.9%, 125/169) , respectively, and the difference was statistically significant (P<0.05). (3) The patency rate of hydrotubation at 12 months after the operation: The patency rate of hydrotubation at 12 months after the operation in the Chitosan and Salvia injection group (85.2%, 150/176) , Chitosan group (81.7%, 143/175) and Salvia group (80% 138/172) was significantly higher than that in the control group (39%, 66/169) , respectively, and the difference was statistically significant (P<0.05). The pregnancy rate at 12 months after the operation in the Chitosan and Salvia injection group (54%, 54/100) , Chitosan group (52%, 52/100) and Salvia group (49%, 49/100) was significantly higher than that in the control group (14%, 14/100). Conclusion Chitosan, Salvia injection, and Chitosan and Salvia injection can effectively reduce the recurrence of tubal adhesion after interventional FTR and increase the pregnancy rate. Using Chitosan and Salvia injection show less complication in patients during and after the operation, which has specific advantage in interventional FTR. Key words: Chitosan; Salvia injection; tubal obstruction; tubal recanalization; adhesion and prevention